Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 1310-1314, 1997;
This Article
Right arrow Full Text
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (17)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sniderman, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sniderman, A. D.
Related Collections
Right arrow Laboratory Management
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 1997;43:1310-1314.)
© 1997 American Association for Clinical Chemistry, Inc.

Articles

Counterpoint To (measure apo)B or not to (measure apo)B: a critique of modern medical decision-making

Allan D. Sniderman

Mike Rosenbloom Laboratory for Cardiovascular Disease, Royal Victoria Hospital, 687 Pine Ave. West, Montreal, Quebec, H3A 1A1. Fax 514-982-0686; e-mail asniderm{at}is.rvh.mcgill.ca

The measurement of apo B provides critical information that is complementary to that provided by the plasma and lipoprotein lipids for the assessment of coronary risk and the choice of appropriate pharmacological therapy. Why then is this measurement not in more widespread clinical use? I suggest two explanations. First, against the evidence, there is a lingering perception that problems persist in its measurement in routine clinical practice. Far from this being the case, however, the measurement of apo B has met every reasonable standard of laboratory precision and reliability to allow its widespread introduction in clinical laboratories. The second impediment is that the introduction of new tests has become subject to the authority of consensus conferences, a new approach to medical decision-making. The number of such conferences is increasing astronomically, and their reports are major determinants of clinical practice and allocation of resources. Notwithstanding the benefits they have brought, here I argue that, just as with any other scientific method, the merits of this new method of decision-making need to be examined critically; for if we do not, a process that was established to introduce change may, in fact, retard it or destroy it altogether.




The following articles in journals at HighWire Press have cited this article:


Home page
 CirculationHome page
I. Shai, E. B. Rimm, S. E. Hankinson, G. Curhan, J. E. Manson, N. Rifai, M. J. Stampfer, and J. Ma
Multivariate Assessment of Lipid Parameters as Predictors of Coronary Heart Disease Among Postmenopausal Women: Potential Implications for Clinical Guidelines
Circulation, November 2, 2004; 110(18): 2824 - 2830.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
R. Jiang, M. B. Schulze, T. Li, N. Rifai, M. J. Stampfer, E. B. Rimm, and F. B. Hu
Non-HDL Cholesterol and Apolipoprotein B Predict Cardiovascular Disease Events Among Men With Type 2 Diabetes
Diabetes Care, August 1, 2004; 27(8): 1991 - 1997.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
S. M. Grundy
Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy
Circulation, November 12, 2002; 106(20): 2526 - 2529.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
S. M. Grundy
Non-High-Density Lipoprotein Cholesterol Level as Potential Risk Predictor and Therapy Target
Arch Intern Med, June 11, 2001; 161(11): 1379 - 1380.
[Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
J. R. Crouse III and C. D. Furberg
Treatment of Dyslipidemia : Room for Improvement?
Arterioscler. Thromb. Vasc. Biol., November 1, 2000; 20(11): 2333 - 2335.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
I. Jungner, S. M. Marcovina, G. Walldius, I. Holme, W. Kolar, and E. Steiner
Apolipoprotein B and A-I values in 147 576 Swedish males and females, standardized according to the World Health Organization–International Federation of Clinical Chemistry First International Reference Materials
Clin. Chem., August 1, 1998; 44(8): 1641 - 1649.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.